Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03186677 |
Recruitment Status :
Completed
First Posted : June 14, 2017
Results First Posted : November 10, 2020
Last Update Posted : November 10, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hemophilia B | Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg Biological: BeneFIX | Phase 1 |
This study is a phase 1, open-label, multi-center, dose-escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of ISU304/CB2679d/Dalcinonacog alfa in previously treated Hemophilia B patients.
This study is comprised of 5 cohorts. Each cohort may receive an intravenous administration of 75 IU/kg, with subcutaneous administrations from 75 IU/kg to 150 IU/kg.
During the study period, a subject may be hospitalized to facilitate the collection of blood samples for pharmacokinetic (PK)/pharmacodynamic (PD) analysis. The Data Safety Monitoring Board (DSMB) and Data Monitoring Committee (DMC) will be operated after the end of Cohorts 1 to 4. These committees will monitor the PK/PD and safety data from each cohort to determine the continuation of next cohort (Cohorts 2 to 5), target dose, and blood sampling period for PK/PD (including timing of collection). Additional subjects may be enrolled in all cohorts or cohorts may be canceled depending on the results of PK/PD analysis. A cohort of subcutaneous dosing at 300 IU/kg was cancelled as single-dose PK is uninformative.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients |
Actual Study Start Date : | June 3, 2017 |
Actual Primary Completion Date : | October 10, 2018 |
Actual Study Completion Date : | February 22, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1
Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
|
Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
Other Name: Dalcinonacog alfa Biological: BeneFIX BeneFIX 75 IU/kg, intravenous administration |
Experimental: Cohort 2
Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
|
Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
Other Name: Dalcinonacog alfa |
Experimental: Cohort 3
Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
|
Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
Other Name: Dalcinonacog alfa |
Experimental: Cohort 4
One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
|
Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
Other Name: Dalcinonacog alfa |
Experimental: Cohort 5
One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
|
Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
Other Name: Dalcinonacog alfa |
- Number of Adverse Events (AEs) After the Administration of Investigational Products (IP) [ Time Frame: Through study completion, an average of 8 days ]The number of reported AEs (local/systemic/other) after IP administration was calculated by cohort.
- Maximum Plasma Concentration (Cmax) [ Time Frame: 0 to 72 hours for Cohorts 1 to 3, 0 to 120 hours for Cohorts 4 and 5 ]Cmax analysis was conducted by cohort as a Factor IX (FIX) potency percent
- Factor IX Inhibitor [ Time Frame: At end of study visit (an average of 8 days) ]
The presence/absence of Factor IX (FIX) neutralizing antibodies was assessed by ELISA anti-drug assay [Dalcinonacog alfa and BeneFIX) and if positive, a modified Nijmegen assay for each subject by cohort at end of study visit.
Measure description: count of participants with neutralizing antibodies. Bethesda Units >0.6 indicates presence of neutralizing antibodies. 1 BU is defined as a 50% reduction in FIX activity when adding participant plasma to a standard with known FIX activity.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Previously treated male patients with moderate or severe hemophilia B (documented FIX activity ≤ 2% and exposed to any FIX product for ≥ 150 exposure days (estimated) at the time of screening)
- Patients must be 12 to 65 years old at the time of screening
- Patients who have discontinued a previously treated FIX product at least 4 days prior to the administration of investigational product
- HIV negative, or if HIV positive with a CD4 count > 200/μL (documented < 200 particles/μL or ≤ 400,000 copies/mL) at the time of screening
- Voluntary consent to participate in the study
Exclusion Criteria:
- Patients with a history or a family history of FIX inhibitors
- Patients with FIX inhibitors (positive result for BeneFIX or ISU304 from inhibitor tests) at the time of screening
- Patients who have a history of thromboembolic events (myocardial infarction, cerebrovascular disease, venous thrombosis, etc.)
- Patients with known hypersensitivity, allergy, or anaphylaxis to any FIX product or hamster protein
- Patients receiving treatment with a FIX product or a bypass agent within 4 half-lives for the agent used (at least 96 hours) prior to the administration of the investigational product
- Patients who have been exposed to long-term administration of immunomodulating agents or immunosuppressants such as α-INF or adrenocortical hormones over the past 3 months or who are currently receiving or planning to receive such treatment during the study period
- Patients who have been administered vaccines during the period of 6 months prior to the administration of the investigational product or plan to receive vaccines during the study period
- Patients with any other co-existing bleeding disorder (Von Willebrand disease, etc.)
- Patients with positive D-dimer results (≥ 0.5 μg/mL) at the time of screening
- Patients with platelet counts less than 100,000/μL at the time of screening
- Patients with ALT, AST levels 5 times greater than upper normal limit or total bilirubin, serum creatinine levels 2 times greater than upper normal limit at the time of screening
- Active hepatitis patients who are HBs Ag positive or anti-HCV Ab positive at the time of screening
- Patients scheduled for surgery during the study period
- Patients participated in another study within 30 days before screening or scheduled to participate in any other study during the study period

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03186677
Korea, Republic of | |
Eulji University Hospital | |
Daejeon, Korea, Republic of | |
Pusan National Univesity Hospital | |
Pusan, Korea, Republic of | |
Yonsei University Medical Center | |
Seoul, Korea, Republic of |
Principal Investigator: | ChurWoo You, PhD | Eulji University Hospital Seo-gu |
Documents provided by ISU Abxis Co., Ltd.:
Responsible Party: | ISU Abxis Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03186677 |
Other Study ID Numbers: |
ISU304-001/CB2679d |
First Posted: | June 14, 2017 Key Record Dates |
Results First Posted: | November 10, 2020 |
Last Update Posted: | November 10, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
ISU304 previously treated Hemophilia B patients FIX |
Factor IX CB2679d Dalcinonacog alfa |
Hemophilia A Hemophilia B Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases |
Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn Genetic Diseases, X-Linked |